SCHEMBL7021095

SCHEMBL7021095

COC(=O)CCn1c(=O)c2cc(C(=O)NCc3ccc(OC)cc3)ccc2n(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
RECQL P46063 1/20 0.51
MMP13 P45452 2/20 0.51
RXFP1 Q9HBX9 2/20 0.50
POLB P06746 1/20 0.47
TP53 P04637 4/20 0.47
NPC1 O15118 1/20 0.46
EPHX2 P34913 1/20 0.46
RAB9A P51151 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC11 Q96DB2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148722 0.92 MAPT (0.51) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7104549 0.90 ALDH1A1 (0.53) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7099302 0.90 MAPT (0.53) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6234634 0.89 MMP13 (0.58) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7623073 0.89 MAPT (0.54) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7015334 0.87 TNF (0.58) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7627970 0.87 MAPT (0.52) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7192894 0.87 RXFP1 (0.51) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7627149 0.86 MAPT (0.51) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL7103427 0.86 MAPT (0.55) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885MEN1 4715/4885KMT2A 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.